AFM-30a

AFM-30a
Identifiers
  • N-[(1S)-4-[(1-amino-2-fluoroethylidene)amino]-1-(1-methylbenzimidazol-2-yl)butyl]-3-oxo-1,2-dihydroisoindole-4-carboxamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC23H25FN6O2
Molar mass436.491 g·mol−1
3D model (JSmol)
  • CN1C2=CC=CC=C2N=C1[C@H](CCCN=C(CF)N)NC(=O)C3=CC=CC4=C3C(=O)NC4
  • InChI=1S/C23H25FN6O2/c1-30-18-10-3-2-8-16(18)28-21(30)17(9-5-11-26-19(25)12-24)29-22(31)15-7-4-6-14-13-27-23(32)20(14)15/h2-4,6-8,10,17H,5,9,11-13H2,1H3,(H2,25,26)(H,27,32)(H,29,31)/t17-/m0/s1
  • Key:CHPVRACBRZIQQU-KRWDZBQOSA-N

AFM-30a is an experimental drug which was the first selective inhibitor to be developed of the enzyme peptidylarginine deiminase 2 (PAD2). It has been used to investigate the role of PAD2 in various inflammatory conditions and development of cancers. It was found to be active against pulmonary fibrosis in a mouse model.

See also